GA
Gowthami Abbireddi
About Gowthami Abbireddi
Gowthami Abbireddi has 17 years in corporate governance. Holds Additional Director and Director roles. Currently with 2 companies, including Biomaacx Nutri Sciences India Private Limited and Sarvani Minerals Private Limited. Formerly with 1 company, such as Implify Technologies India Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Biomaacx Nutri Sciences India Private Limited
U15500AP2009PTC065559
|
Additional Director | 01 Sep 2022 | 2009 | Active |
Sarvani Minerals Private Limited
U01100AP2009PTC063160
|
Director | 06 Sep 2024 | 2009 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Implify Technologies India Private Limited
U72900TG2008PTC062214
|
Director | 15 Dec 2008 | 2008 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Gowthami Abbireddi
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gowthami Abbireddi
Gowthami Abbireddi has 17 years in corporate governance. Holds Additional Director and Director roles. Currently with 2 companies, including Biomaacx Nutri Sciences India Private Limited and Sarvani Minerals Private Limited. Formerly with 1 company, such as Implify Technologies India Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Gowthami Abbireddi is associated with 2 companies as Additional Director and Director.
Gowthami Abbireddi has expertise in General Business, Technology.
Gowthami Abbireddi has 17 years in corporate governance.